The doses of ShK-223 (IC50 25 p.m.)and PAP-1 (IC50 for 2 nM) were chosen considering their Kv1.3 blocking potency and are based on previously reported efficacy in rat models of experimental autoimmune encephalomyelitis (EAE) or of ischemic stroke (Tarcha et al., 2012; Chen et al., 2018). This evidence concerns the gene KCNA3 and experimental autoimmune encephalomyelitis.